JSPR – jasper therapeutics, inc. - class a (US:NASDAQ)
Stock Stats
News
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $68.00 price target on the stock.
Jasper Therapeutics, Inc. (NASDAQ: JSPR) is now covered by analysts at BMO Capital Markets. They set an "outperform" rating and a $63.00 price target on the stock.
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma
We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate [Yahoo! Finance]
Is Jasper Therapeutics (JSPR) the Best Multibagger Stock to Buy Heading into 2025? [Yahoo! Finance]
Form 4 Jasper Therapeutics, For: Dec 12 Filed by: Mahal Jeetinder Singh
Form 144 Jasper Therapeutics, Filed by: Mahal Jeetinder Singh
Form SC 13G/A Jasper Therapeutics, Filed by: Avidity Partners Management LP
Form SC 13G/A Jasper Therapeutics, Filed by: Soleus Private Equity Fund III, L.P.
Form SC 13G Jasper Therapeutics, Filed by: BlackRock, Inc.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.